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Abstract
The transcription factor coregulator Casein kinase IIβbinding protein 2 or CR6-interacting factor 1
(CKβBP2/CRIF1) binds the androgen receptor (AR) in prostate cancer cells and in response to
dihydrotestosterone localizes with AR on the prostate-specific antigen gene enhancer, but does not
bind DNA suggesting CKβBP2/CRIF1 localization in chromatin is determined by AR. In this
study we show also that CKβBP2/CRIF1 inhibits wild-type AR and AR N-terminal transcriptional
activity, binds to the AR C-terminal region, inhibits interaction of the AR N- and C-terminal
domains (N/C interaction) and competes with p160 coactivator binding to the AR C-terminal
domain, suggesting CKβBP2/CRIF1 interferes with AR activation functions 1 and 2. CKβBP2/
CRIF1 is expressed mainly in stromal cells of benign prostatic hyperplasia and in stroma and
epithelium of prostate cancer. CKβBP2/CRIF1 protein is increased in epithelium of androgen-
dependent prostate cancer compared to benign prostatic hyperplasia and decreased slightly in
castration recurrent epithelium compared to androgen-dependent prostate cancer. The
multifunctional CKβBP2/CRIF1 is a STAT3 interacting protein and reported to be a coactivator of
STAT3. CKβBP2/CRIF1 is expressed with STAT3 in prostate cancer where STAT3 may help to
offset the AR repressor effect of CKβBP2/CRIF1 and allow AR regulation of prostate cancer
growth.
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1. Introduction
The androgen receptor (AR) has an essential role in human male reproductive tract
development and function as evidenced by AR gene mutations that result in the androgen
insensitivity syndrome (Quigley et al., 1995). AR is a DNA binding transcription factor that
directs the cellular actions of androgens by acting as a docking platform for transcription
coregulators. Epithelium and stroma of human prostate are targets of androgen action and
depend on AR and its natural ligand, dihydrotestosterone (DHT) for growth and male sexual
development. Similarly, neoplastic growth of the prostate is AR dependent and regresses
initially in response to androgen deprivation therapy. Evidence indicates that AR has a
central role in the eventual relapse of prostate cancer during androgen deprivation therapy
(referred to as castration-recurrent or castration-resistant growth) (Grossman et al., 2001;
Gregory et al., 2001a, 2001b; Ponguta et al., 2008; Mohler et al., 2004; Titus et al., 2005;
Yuan and Balk, 2009; Agoulnik and Weigel, 2006; Heemers and Tindall, 2007).
Transcriptional functions of AR involve the concerted actions of coactivators and
corepressors (Heemers and Tindall, 2007; Wang et al., 2005; Burd et al., 2006) that regulate
chromatin modifying complexes and gene transcription (reviewed in Perissi et al., 2010;
Battaglia et al., 2010)
CKβBP2/CRIF1 cDNA was isolated originally in p53 stably transformed colon cancer cell
lines (Horikoshi et al., 1999) and later identified as a protein that interacts with the β subunit
of protein kinase CK2 (Ahn et al., 2001), but its influence on the function of protein kinase
CK2 remains unknown. CKβBP2/CRIF1 was identified also as one of a number of
papilloma virus L2 interacting nuclear proteins (Gornemann et al., 2002). Indication of a
function for CKβBP2/CRIF1 was revealed when Chung et al. (2003) reported CKβBP2/
CRIF1 is a GADD45γbinding protein. GADD45α, β and γ are DNA damage inducible
proteins (Carrier et al., 1999) that inhibit the cell cycle. CKβBP2/CRIF1 interacted with
GADD45γ and had a similar function with respect to cell cycle inhibition (Chung et al.,
2003).
Here we report a mechanism for the AR corepressor activity of CKβBP2/CRIF1 (Su JH et
al. 2008) and identify a small fragment of CKβBP2/CRIF1 that inhibits the transcriptional
activity of AR. CKβBP2/CRIF1 interacted with the C- and N-terminal regions of AR,
disrupted the AR N/C interaction and competed with TIF2 binding to the AR C-terminus.
CKβBP2/CRIF1 also inhibited the constitutive activity of an AR N-terminal-DNA binding
domain fragment. CKβBP2/CRIF1 protein expression was analyzed in prostate cancer where
AR has a major role in neoplastic growth and progression. In benign prostatic hyperplasia,
CKβBP2/CRIF1 protein was expressed mainly in fibromuscular stromal cells. In androgen-
dependent prostate cancer, CKβBP2/CRIF1 protein was increased in epithelial cells
compared to benign prostatic hyperplasia. However, it was reduced in epithelial cells of
castration-recurrent compared to androgen-dependent prostate cancer.
STAT3 is known to promote prostate cancer progression. In prostate cancer tissue
microarrays, we show that CKβBP2/CRIF1 and STAT3 proteins are present in the same
cellular locations. CKβBP2/CRIF1 is a STAT3 coactivator (Kwon et al., 2008). CKβBP2/
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CRIF1 binding and coactivation of STAT3 may offset the AR repressor effect of CKβBP2/
CRIF1 and help maintain a selective advantage for prostate cancer cell growth.
2. Materials And Methods
2.1 Yeast two hybrid screening
The AR vector pBDGAL4CAM-481–919 that expresses the carboxyl-terminal portion of the
human AR N-terminal, DNA and ligand-binding domains was used as bait in yeast two-
hybrid screening of a human epithelial cervical carcinoma HeLa cell cDNA library in GAD-
GH (Clontech Laboratories, Inc., Palo Alto, CA) (gift of Yue Xiong, University of North
Carolina at Chapel Hill). Yeast strain Hf7c co-transformed with HeLa cell cDNAs was
plated on synthetic medium without Leu, Trp and His containing 5 mM 3-amino-1,2,4-
triazole and 1 μM DHT. After 5 to 7 days in culture, colonies were selected for
βgalactosidase assay. cDNAs from βgalactosidase positive yeast colonies were rescued using
standard procedures. Liquid βgalactosidase assays were performed as described for the
Clontech Matchmaker system (Clontech protocol PT3247-1).
2.2 Plasmids
The coding region for CKβBP2/CRIF1 was excised from pGAD-GH using EcoRI and XhoI
and cloned into the same restriction sites in pSG5 (Stratagene) with a FLAG tag added to
make pSGFLAG-CKβBP2/CRIF1-7-222. pSG5 (pSG) was chosen for these studies because
its SV40 promoter was not affected by pSGFLAG-CKβBP2/CRIF1, whereas the activity of
a CMV promoter was increased by pSGFLAG-CKβBP2/CRIF1. The cytomegalovirus-
luciferase reporter vector was provided by William M. Wood and Arthur Gutierrez-
Hartmann and SV40-luciferase was from Stratagene. pSGFLAG-CKβBP2/CRIF1-7-222 was
digested with PstI, gel purified and the 6 kb fragment self-ligated to create pSGFLAG-
CKβBP2/CRIF1-7-157. The small PstI fragment was treated with T4 DNA polymerase and
cloned into pSGFLAG EcoRV to create pSGFLAG-CKβBP2/CRIF1-158-206. Full-length
CKβBP2/CRIF1 was obtained from ATCC (catalog #6709344). pOBT7 containing full-
length CKβBP2/CRIF1 was digested with EcoRI, treated with Klenow and digested with
XhoI. The full-length fragment was cloned into pSGFLAG treated with BamHI, filled-in
with Klenow followed by XhoI digestion to make pSGFLAG-CKβBP2/CRIF1-2-222. The
full-length clone does not contain the codon T187C missense mutation we found in the
pSGFLAG-CKβBP2/CRIF1-7-222 isolated by yeast two-hybrid screening. Human AR
expression vectors GAL-AR-624-919, VP-AR-1-660 and VP-TIF2.1 (TIF2-624-1287) were
described (Tan et al., 2000; He et al., 1999). The prostate-specific antigen (PSA) luciferase
(Luc) reporter vector PSA-Enh-Luc provided by Michael Carey, University of California at
Los Angeles, contains the PSA upstream enhancer region (Huang et al., 1999). MMTV-Luc
reporter gene was provided by Stanley M. Hollenberg and Ron M. Evans (Salk Institute).
2.3 Transient cotransfection assay
Cotransfection assays were performed in triplicate (Tan et al., 2000; He et al., 1999; Bai et
al., 2005, 2008). In brief, African green monkey kidney CV1 cells were maintained in 10%
fetal bovine serum containing high glucose and antibiotics. Cells (4.2 × 105) were plated in
6 cm (28 cm2) culture dishes. On the following day when 70-80% confluent, cells were
transfected with MMTV-Luc (0.5 μg) and various amounts of expression vectors using the
CaPO4 method. After 15% glycerol shock for 4 min, cells were incubated in Dulbecco's
modified Eagle's medium-H (DMEM-H) without phenol red and serum in the absence and
presence of DHT. The next day media were removed and replaced with fresh media of the
same composition. Incubation was continued for 20 h. Cells were harvested in lysis buffer
and luciferase activity was measured in an automated multiwell luminometer. Results are
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representative of at least three individual experiments performed in triplicate. Error bars
represent ± SEM.
CWR-R1 cells were maintained in Richter's improved minimal essential medium (Irvine
Scientific, Santa Ana, CA) supplemented with 10 mM nicotinamide, 5 μg/ml insulin, 5 μg/
ml transferrin, 5 ng/ml selenium, 100 units/ml penicillin, 100 μg/ml streptomycin and 2%
fetal bovine serum. Cells were plated in 6 well plates (3.5 × 106 cells per well). Two hybrid
interaction assays were performed in HeLa cells (Bai et al., 2005, 2008; Gregory et al.,
2004) maintained in Eagle's minimum essential medium supplemented with 10% fetal
bovine serum (Gemini or Hyclone), penicillin, streptomycin and 2 mM L-glutamine. HeLa
cells (5 × 104 cells/well in 12 well plates) were transfected with 0.1 μg of 5xGAL4Luc3, 50
ng of VP-AR-1-660 or VP-TIF2.1-624-1287 and 50 ng GAL-AR-624-919. DNA was added
to 43 μl of serum-free medium and 0.6 μl of FuGENE-6 reagent per well. After 15 min
incubation, 40 μl of FuGENE DNA mixture was added to each well containing 1 ml
medium. The next day, cells were washed with phosphate buffered saline (PBS) and 1 ml/
well serum-free medium lacking phenol red and containing the indicated steroids was added
and incubated overnight at 37°C. The next day cells were washed with PBS and assayed for
luciferase activity after harvesting in 0.25 ml lysis buffer.
2.4 Glutathione S-transferase (GST) pull-down assays
GST binding assays were performed as described (Tan et al., 2000). In brief, pSGFLAG-
CKβBP2/CRIF1 was incubated with [35S]methionine and rabbit reticulocyte lysate using the
TnT T7 Quick-coupled Transcription/Translation System kit (Promega). Labeled protein
was distributed equally among incubations with GST-glutathione-Sepharose control and
recombinant GST-fusion proteins bound to glutathione-Sepharose. After incubation and
washes in the presence of 0.1 nM DHT, labeled protein was eluted by boiling in SDS buffer
and separated by SDS-PAGE. Gels were dried and exposed to Kodak x-ray film.
2.5 Coimmunoprecipitation
COS cells cultured in Dulbecco's modified Eagle's medium-H in 10 cm dishes were
transfected with pSGFLAG-CKβBP2/CRIF1-7-222, -7-157 or -158-206 in combination with
pSG-AR using the DEAE-dextran method (Tan et al., 2000). Two days after transfection,
cells were harvested in PBS and lysed in 50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP40,
50 mM NaF with the addition of 0.8 mM DTT, 1 mM PMSF and a protease inhibitor
cocktail pellet (Roche). 25 μl anti-FLAG M2 agarose gel (Sigma) was added and incubated
overnight at 4°C. Beads were washed several times with lysis buffer and bound proteins
eluted in SDS sample buffer, separated in SDS-PAGE and western blotted using FLAG M2
or AR32 antibody (Quarmby et al., 1990). The FLAG-STAT3 expression vector was pRC/
CMV-STAT3 from Addgene.
2.6 Immunofluorescence microscopy
COS cells seeded on cover slips in 12-well plates (1.25 × 105 cells/well) were transfected
using the Effectene method with 0.1 μg pCMV-AR, pSGFLAG-CKβBP2/CRIF1 or
pSGFLAG in the presence and absence of DHT as described (Bai et al., 2005). Cells were
fixed in 3% paraformaldehyde in PBS for 10 min at room temperature and permeabilized
with 0.2% Triton X-100 in PBS for 5 min at 4°C. After rinsing with PBS 3 times, 0.5%
bovine serum albumin in PBS was added and cells incubated 30 min at room temperature.
Cells were incubated with primary antibodies anti-AR Abcam ab3510 (1:250 dilution) and/
or anti-FLAG (1:1000 dilution) for 1 h at room temperature. After washing with PBS, a 1:50
dilution of secondary fluorescent antibody was added and incubated for 30 min. Microscopy
was performed using an Olympus BX60 microscope with 40× objective, magnification
400×. Rabbit anti-AR ab3510 was from Abcam, Cambridge, MA. Mouse anti-FLAG
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antibody was from Sigma. Fluorescein (FITC)-conjugated AffiniPure donkey anti-rabbit
IgG and rhodamine (TRITC)-conjugated AffiniPure donkey anti-mouse IgG were from
Jackson ImmunoResearch, West Grove PA.
2.7 Chromatin immunoprecipitation
CWR-R1 human prostate cancer cells (107/10 cm dish) were serum starved for 24 h. The
next day, cells were changed to serum-free medium containing 10 nM methyltrienolone
(R1881), incubated for various times and cross-linked using 1% formaldehyde for 10 min at
room temperature followed by 5 min with 0.125 M glycine at room temperature. Cells were
washed and harvested in PBS. Cell pellets were resuspended in 10 mM Hepes, pH 7.9, 0.5%
Triton X-100, 1.5 mM MgCl2, 10 mM KCl, 0.6 mM phenylmethylsulfonyl fluoride, 2.5 nM
pepstatin A, 30 nM leupeptin and 0.5 mM DTT. After a 10 min incubation at 4°C, cell
pellets were resuspended in 20 mM Hepes, pH 7.9, 25% glycerol, 0.5% Triton X-100, 0.42
M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA with the same amount of proteinase inhibitors.
Following 20 min incubation at 4°C, cells were sonicated at 21% power 40 times, 0.5 sec
each time and the procedure repeated to obtain 100-1000-bp DNA fragments. Following 10
min centrifugation, clarified lysates were diluted 1:1 with 1% Triton X-100, 2 mM EDTA,
50 mM NaCl, 20 mM Tris-HCl, pH 8.1 containing the same amounts of protease inhibitors.
Samples were precleared for 1 h at 4°C with 20 μl of protein-A-agarose (Sigma).
Immunoprecipitation was performed overnight at 4°C with the addition of 5 μg normal
rabbit serum IgG (Santa Cruz Biotechnology sc-2027), rabbit anti-AR H-280 (Santa Cruz
Biotechnology sc-13062) or CKβBP2/CRIF1 antibody. Samples were incubated with 20 μl
of protein-A agarose for 3 h and protein-A agarose pellets washed sequentially with 1 ml
each of low salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH
8.1 and 150 mM NaCl), high salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20
mM Tris-HCl, pH 8.1 and 500 mM NaCl), LiCl buffer (0.25 M LiCl, 1% Triton X-100, 1
mM EDTA, 10 mM Tris-HCl, pH 8.1 and 1% sodium deoxycholate) and 2× 1 ml TE buffer
(10 mM Tris-HCl, pH 8.1, 1 mM EDTA). Immunoprecipitated DNA was eluted in 50 μl of
1% SDS, 0.1 M NaHCO3 3 times at 25°C for 15 min each. The resulting DNA was de-
crosslinked by adding 6 μ of 5 M NaCl, incubated at 65°C overnight, followed by 45°C
incubation with the addition of 2.4 μl of 0.5 M EDTA, 4.8 μl of 2 M Tris-HCl, pH 6.5, 2 μl
of 10 mg/ml proteinase K and 2 μl of 10 mg/ml RNase A for 1 h. DNA was purified and
PCR performed in 10 μl reactions using SYBR green and PSA gene upstream enhancer
primers 5′-GGGACAACTTGCAAACCTG-3′ and 5′-GTATCTGTGTGTCTTCTGAGC-3′
at 95°C for 20 min, 40 cycles of 95°C for 30 sec, 57°C for 30 sec, 72°C for 45 sec to
amplify a 285 bp fragment from the -4234 to -3950 5′-flanking region.
2.8 DNA binding assay
COS cells (1.8 × 106/10 cm dish) transfected with 5 μg empty vector control (pSG-FLAG),
pSGFLAG-AR or CKβBP2/CRIF1 in the presence of 10 nM DHT were harvested in PBS
and lysed with 250 μl buffer containing 1% Triton X-100, 1% sodium deoxycholate, 0.15 M
NaCl, 0.1% SDS, 50 mM NaF, 2 mM sodium vanadate, 2 mM EDTA, 50 mM Tris-HCl, pH
7.6 plus 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and complete protease
inhibitor cocktail (Roche Applied Science). The same PSA upstream enhancer DNA
amplified in the ChIP assay (5 μl of 10 μlM stock) was added to 50 μl COS cell protein
extract and 90 μl DNA binding buffer (10 mM Tris, pH 7.5, 25 mM KCl, 0.1 mM EDTA, 1
mM DTT, 10% glycerol) with 1 mM ZnSO4, incubated for 3 h at 4°C, 25 μ of M2-FLAG
antibody-agarose beads added and incubation continued overnight at 4°C. The next day,
agarose beads were washed 3 times with 1 ml DNA binding buffer with ZnSO4. DNA
binding buffer (100 μl) containing RNase and proteinase K was added to the beads and
incubated at 65°C for 1 h. The mixture was phenol extracted, ethanol precipitated, dissolved
in 10 μl of H2O and separated in a 1% agarose gel. The area of gel corresponding to the PSA
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upstream enhancer DNA was cut out, DNA was eluted and used for RT-PCR. The amount
of RT-PCR amplified DNA was calculated based on a PSA standard curve using genomic
DNA. Fold binding was calculated against empty vector control (pSGFLAG) set to 1.
2.9 siRNA transfection
CKβBP2/CRIF1 siRNAs were obtained from Dharmacon, Chicago, IL (5′-3′ sense
sequences siRNA1 197CUAAGCAGUUCGCGCGUUAUU,
siRNA2 264GAGCUGGAGGCCGAAGAACUU). siRNAs were transfected into COS cells
along with pSGFLAG-CKβBP2/CRIF1 or pSGFLAG empty vector using Lipofectamine
2000 (Invitrogen) according to the manufacture's instructions. COS cells were plated in 6 cm
dishes at 3 × 105/dish (50-60% confluent) and cultured in DMEM-H without the addition of
antibiotics. Lipofectamine diluted 1:10 in Opti-MEM medium was incubated at room
temperature for 5 min and added to Eppendorf tubes containing siRNA and vector DNA,
incubated an additional 20 min at room temperature and mixed before adding to the cells.
COS cells were incubated for 48 h at 37°C and harvested in PBS. CV1 cells plated in 6 cm
dishes at 4.5 × 105 cells/dish and cultured in DMEM-H. CWR-R1 cells in 6 well dishes at 4
× 105 cells/well were cultured in Richter's medium transfected with Lipofectamine as above.
2.10 Immunoblots
Antibodies were raised in rabbits with CKβBP2/CRIF1 peptide 144CEKAQADKERRARL-
QA158 (Pocono Rabbit Farm & Laboratory, Inc. PA) and purified using peptide antigen
affinity chromatography. For antibody assay, western blots were performed using protein
extracts from COS cells transfected with pSGFLAG or pSGFLAG-CKβBP2/CRIF1.
The small repressor CKβBP2/CRIF1 protein fragment amino acids158-206 was expressed in
COS cells and identified by chromatography on a 4-20% gradient gel.
2.11 Immunohistochemistry
Surgical specimens of prostate were collected according to NIH guidelines with approval by
the IRB of Roswell Park Cancer Institute and the University of North Carolina School of
Medicine at Chapel Hill. BPH cores were taken from radical prostatectomy specimens at
sites away from the cancer. Tissue microarray (Titus et al., 2005) was performed as follows:
formalin-fixed, paraffin-embedded tissue microarray sections were incubated at 70°C for 15
min, deparaffinized in toluene and rehydrated through graded alcohols to phosphate buffered
saline. Endogenous peroxidase was blocked using 5% H2O2 in 83% methanol for 30 min at
room temperature. For antigen retrieval, slides were placed in 0.01 M sodium citrate, 0.01 M
critic acid, pH 6.0 for 15 min in a microwave on high setting followed by 15 min cool down
incubation in the citrate solution (Balaton et al., 1993). Sections were blocked with 1.5%
normal goat serum (for anti-CKβBP2/CRIF1) or rabbit serum (for anti-STAT3) for 20 min
and incubated overnight at 4°C with anti-CKβBP2/CRIF1 (1:100 dilution) or anti-STAT3
ab30646 antibodies (1:100 dilution, Abcam). Slides were blocked in normal serum for 10
min and incubated at room temperature for 30 min with biotinylated anti-rabbit IgG (1:200
dilution) (Vector Labs, Burlingame, CA) followed by a 30 min incubation at room
temperature with the Elite Avidin DH-biotinylated horseradish peroxidase H complex (1:50
dilution) (Vector Labs). Sections were incubated for 10 min with 3, 3′diamino-benzidine
(DAB Peroxidase Substrate Kit SK-4100, Vector Labs) and counterstained with Gill's
hematoxylin (Protocol Hematoxylin Gill-3X, Fisher Scientific). APERIO Imagescope
software was used to capture and store the images. Defective cores with tissue damage were
excluded from scoring for CKβBP2/CRIF1 and STAT3 staining . The analysis shown in Fig.
8 included 25 cores each of BPH, androgen-dependent and castration-recurrent prostate
cancer.
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RNA was extracted using Trizol (Qiagen) according to manufacturer's recommendations.
RNA (2 μg) was reverse-transcribed using SuperScript II Reverse Transcriptase
(Invitrogen). RT-PCR using QuauntiTech SYBR Green (Qiagen) was performed in a Roche
Life Cycler using 100 ng cDNA. Gene expression calculation was based on the standard
curve. Relative expression was defined as sample mRNA expression divided by internal
control. Standard curves for the internal control gene cyclophilin (peptidylprolyl isomerase
A, PPIA) or CKβBP2/CRIF1 were prepared in a RT-PCR assay using serial dilutions of the
cDNA. Primers for CKβBP2/CRIF1 were 5′-GGACCCCGCACAGCCAAGATGG-3′ and
5′-GAGGCTGCTGGGTCTTGAGC-3′, for PPIA 5′-GGGCCGCGTCTCCTTTGAGC-3′
and 5′-CATTCCTGGACCCAAAGCGCTC-3′.
2.12 Statistical Analysis
Analyses were performed using Student's t-test and Microsoft Excel Tools. Error bars
represent ± SEM. Differences were considered significant at p<0.05.
3. Results
3.1 CKβBP2/CRIF1 interacts with ligand-activated AR in yeast
Yeast two hybrid screening of a HeLa cell cDNA library was performed using as bait human
AR-481-919 carboxyl-terminal fragment that includes a portion of the N-terminal domain
and DNA and ligand binding domains. Approximately 6 × 105 yeast library colonies were
screened and 6 colonies were positive in the βgalactosidase assay. One clone was protein
kinase CK2βbinding protein 2 (CKβBP2) (Ahn et al., 2001; Chung et al., 2003) known also
as a GADD45γ interacting protein, CR6-interacting factor 1 (CRIF1) and referred to here as
CKβBP2/CRIF1.
The interaction of CKβBP2/CRIF1 with AR-481-919 was analyzed using a yeast liquid β
galactosidase assay. Yeast strain Y190 transformed with pBDGAL-CAM-AR-481-919 and
pGADGH-CKβBP2/CRIF1 or pGADGH empty vector control were grown in selective
medium with or without androgen. There was a slight increase in βgalactosidase activity
over the control background in the absence of CKβBP2/CRIF1, however activity increased
8-fold over background in the presence of DHT when both CKβBP2/CRIF1 and AR were
present (Fig. S1A). This was 4-fold greater than the increase βgalactosidase activity in the
absence of CKβBP2/CRIF1, indicating a DHT-dependent interaction of CKβBP2/CRIF1 and
AR. The HeLa cell cDNA clone lacks the first 6 amino acid residues MAASVR compared
to the published sequence of CRIF1 (Ahn et al., 2001) and there is a single nucleotide (C to
T) difference from the published sequence changing Arg 187 to Cys (Fig. S1B).
3.2 CKβBP2/CRIF1 over-expressed in COS cells interacts with AR in the nucleus and
inhibits AR transcriptional activation
Immunostaining for AR and CKβBP2/CRIF1 over-expressed in COS cells showed nuclear
localization in the presence of DHT (Fig. 1A). An androgen-dependent interaction between
CKβBP2/CRIF1 and AR was suggested by co-immunoprecipitation in COS cells (Fig. 1B).
Immunoprecipitation with FLAG antibody showed AR bound to FLAG-CKβBP2/
CRIF1-7-222 and to FLAG-CKβBP2/CRIF1-1-222 in the presence of DHT, with no
detectable interaction in the absence of DHT. The results indicate that CKβBP2/CRIF1
binds to the DHT-activated AR.
Chromatin immunoprecipitation showed that following exposure to R1881, AR and
CKβBP2/CRIF1 located to chromatin at 3 and 6 h in the region of the PSA gene upstream
enhancer (Fig. 1C). AR bound the PSA gene upstream enhancer DNA while CKβBP2/
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CRIF1 did not (Fig. 1D), suggesting CKβBP2/CRIF1 was bound to AR at this chromatin
site.
3.3 Repressor effect of CKβBP2/CRIF1 on DHT-dependent AR transcriptional activity
CV1 cells were transfected with MMTV-Luc and full-length AR together with pSGFLAG-
CKβBP2/CRIF1 or pSGFLAG vector control (Fig. 2). Luciferase activity with pSGFLAG-
CKβBP2/CRIF1 (0.1 or 0.5 μg) was decreased compared to the pSGFLAG empty vector
control. The results suggested a repressor effect of CKβBP2/CRIF1 on AR transactivation.
In similar assays, CKβBP2/CRIF1 inhibited transcriptional activity of the human
progesterone receptor-B but not the glucocorticoid receptor (Fig. S2).
3.4 CKβBP2/CRIF1 inhibits the AR N/C interaction and binding of the p160 coactivator TIF2
to the AR C-terminal region
We used a mammalian two-hybrid assay to test the influence of CKβBP2/CRIF1 on AR N-
terminal region binding to the AR C-terminal region (AR N/C interaction) (He et al., 2000,
2001, 2004). HeLa cells were transfected with a 5XGal4Luc3 reporter gene together with
GAL-AR-624-919 (AR C-terminal region linked to the GAL4 DNA binding domain) and
VP-AR-1-660 (AR N-terminal and DNA binding domain linked to the VP16 activation
domain). A strong DHT-dependent AR N/C interaction between VP-AR-1-660 and GAL-
AR-624-919 was inhibited by CKβBP2/CRIF1 compared to the pSGFLAG control (Fig. 3A,
left).
A similar experiment indicated that CKβBP2/CRIF1 inhibited binding of the p160
coactivator TIF2 to the AR C-terminal region. With co-transfection of control pSGFLAG,
VP-TIF2.1 interacted strongly with the C-terminal Gal-AR-624-919, but this interaction was
reduced markedly in the presence of CKβBP2/CRIF1 (Fig. 3A, right). Thus, in addition to
its inhibitory effect on the AR N/C interaction, CKβBP2/CRIF1 interfered with the binding
of TIF2 to the AR C-terminal region.
CKβBP2/CRIF1 inhibition of AR transcriptional activation was overcome by an increase in
TIF2 (Fig. 3B). CV1 cells were cotransfected with pSG-AR and the MMTV-Luc reporter
vector together with 0.5 μg pSGFLAG control or pSG-CKβBP2/CRIF1 expression vector,
each with either pSGTIF2 (0.1 or 0.5 μg) or the same amount of pSGFLAG empty vector
control. In the presence of control, TIF2 increased DHT-dependent luciferase activity (Fig.
3B, left). When cells were cotransfected with CKβBP2/CRIF1 (0.5 μg) the increase with
TIF2 (0.1 μg) was inhibited. However, the increase with TIF2 (0.5 μg) was not inhibited by
CKβBP2/CRIF1 (0.5 μg) (Fig. 3B, right) consistent with competitive inhibition.
3.5 CKβBP2/CRIF1 interacts preferentially with the AR C-terminal region in cell-free
binding assays
Binding of [35S] CKβBP2/CRIF1-7-222 to GST-AR N-terminal, DNA binding domain or C-
terminal ligand binding domain was compared in a glutathione-Sepharose affinity matrix
assay. CKβBP2/CRIF1 binding to the AR ligand binding domain (AR amino acid residues
624-919) was evident (Fig. 3C), whereas binding to the N-terminal (1-503) and DNA
binding domain (544-634) regions of AR was less and revealed only by longer exposure of
the x-ray film (not shown). In a similar assay, there was no direct interaction between
CKβBP2/CRIF1 and TIF2 (data not shown).
Binding of CKβBP2/CRIF1 to the C-terminal region of AR and the ability of TIF2 to
overcome CKβBP2/CRIF1 inhibition of AR transcriptional activity suggested the CKβBP2/
CRIF1 and TIF2 interaction sites in the AR C-terminal region overlap. It is known that an
LXXLL motif in TIF2 interacts with AR activation function 2 (AF2) in the AR C-terminal
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region and that TIF2 can compete with the AR N-terminal FXXLF motif binding to AF2 (He
et al., 1999, 2001, 2004).
3.6 CKβBP2/CRIF1 inhibits constitutive transcriptional activity of AR N-terminal-DNA
binding domain
An influence of CKβBP2/CRIF1 on the AR N-terminal activation function was explored
using the constitutively active AR-1-660 that includes the AR N-terminal region and DNA
binding domain. When CKβBP2/CRIF1 was co-transfected in CV1 cells with pCMV-
AR-1-660 and MMTV-Luc, AR-1-660 induced activity was inhibited compared to the pSG-
FLAG control vector (Fig. 4A).
Melanoma antigen-A11 (MAGE-A11) is an AR coregulator that binds the AR N-terminal
FXXLF motif region and increases AR transcriptional activity by stabilizing AR and
recruiting TIF2 and p300 (Bai et al., 2005, 2008; Askew et al., 2009, 2010). To further
characterize the influence of CKβBP2/CRIF1 on the AR N-terminal activation function,
CV1 cells were transfected with pCMV-AR-1-660 and PSA-Enh-Luc with and without
pSG-MAGE (Fig. 4B). AR-1-660 induced luciferase activity was increased by MAGE-A11
and inhibited by CKβBP2/CRIF1. The results were consistent with an interaction of
CKβBP2/CRIF1 with the AR N-terminal region. CKβBP2/CRIF1 may interfere with binding
of MAGE-A11, TIF2 or p300 to the AR N-terminal region.
3.7 C-terminal region of CKβBP2/CRIF1 is sufficient for inhibition of AR transcriptional
activation
The AR inhibitory region of CKβBP2/CRIF1 was investigated using peptide of CKβBP2/
CRIF1 (Fig. 5). CKβBP2/CRIF1-158-206 inhibition of DHT-dependent AR transcriptional
activity was stronger than CKβBP2/CRIF1-7-157 and similar to that of the nearly full-length
CKβBP2/CRIF1-7-222 (Fig. 5A). Since CKβBP2/CRIF1-158-206 contains a nuclear
translocation-like sequence, an explanation for its stronger inhibitory activity might be
greater availability to AR in nuclei. However, CKβBP2/CRIF1 fragments 7-157 and
158-206 were nuclear in COS cell expression experiments (results not shown) and they co-
immunoprecipitated with full-length AR in a DHT-dependent manner (Fig. 5B). The
CKβBP2/CRIF1-158-206 peptide was identified by separation on a 4-20% SDS-glycine
gradient gel (Fig. S4).
CKβBP2/CRIF1-158–206 contains a predicted αhelical motif sequence 175FQELL179similar
to the AR N-terminal FXXLF motif that binds AR AF2 (He et al., 2004, 2000). Mutation of
the FXXLF motif to 175FQEAA179 i in the AR N-terminus abolished its ability to bind AR
AF2 (He et al. 2000). However, CKβBP2/CRIF1-7–222 containing the mutant
sequence 175FQEAA179 (FXXAA) retained the ability to inhibit AR transcriptional activity
(Fig. 5A) and to bind AR in a DHT-dependent manner (Fig. 5C), suggesting
the175FQELL179 motif was not required for the inhibitory interaction of CKβBP2/
CRIF1-7-222 with AR.
3.8 siRNA knockdown of endogenous CKβBP2/CRIF1 in CWR-R1 human prostate cancer
cells increases AR transcriptional activity
CWR-R1 cells express AR at levels sufficient for reporter gene analysis of DHT-dependent
transcription. CKβBP2/CRIF1 inhibited endogenous AR activity in transient transfection
assays in CWR-R1 cells transfected with MMTV-Luc together with pSGFLAG-CKβBP2/
CRIF1-2–222 or -7–222 (Fig. 6A).
CWR-R1 cells expressed CKβBP2/CRIF1 protein by immunostaining (not shown). siRNA
knockdown indicated a repressor influence of endogenous CKβBP2/CRIF1 on AR
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transcriptional activity. In initial experiments, CKβBP2/CRIF1 siRNAs were tested in COS
cells for their ability to inhibit overexpression of recombinant CKβBP2/CRIF1. siRNA1
eliminated detectable CKβBP2/CRIF1 protein, whereas siRNA2 reduced it by only about
20% of the control (Fig. 6B). The siRNAs were also tested in DHT-dependent transcription
assays using CV-1 cells cotransfected with AR and MMTV-Luc with and without siRNA. In
this assay, CKβBP2/CRIF1 inhibition of DHT and AR-stimulated luciferase activity was
prevented by siRNA1 but not by siRNA2 (Fig. 6C).
Knockdown of endogenous CKβBP2/CRIF1 in CWR-R1 cells transfected with MMTV-Luc
was performed with increasing amounts of siRNA-1 or 2 in the presence and absence of
DHT. At each siRNA concentration, DHT-stimulated luciferase activity was 2–3 fold higher
with siRNA-1 compared to siRNA-2 (Fig. 6D). The results are consistent with a repressor
effect of endogenous CKβBP2/CRIF1 on AR transcriptional activity in CWR-R1 cells.
Repression of AR by endogenous CKβBP2/CRIF1 was released by siRNA1 more than by
siRNA2.
3.9 CKβBP2/CRIF1 mRNA expression in human prostate cancer
AR is expressed in stroma and epithelium of benign prostatic hyperplasia (BPH) and
prostate cancer. Levels of CKβBP2/CRIF1 mRNA did not differ significantly in clinical
specimens of BPH, androgen-dependent and castration-recurrent prostate cancer tissue (Fig.
7).
3.10 CKβBP2/CRIF1 protein is expressed together with STAT3 in stroma and epithelium of
prostate cancer
Because of the reported interaction and transcriptional coactivator effect of CKβBP2/CRIF1
on STAT3 (Kwon et al., 2008), we confirmed the direct interaction of CKβBP2/CRIF1 and
STAT3 (Fig. S3) and performed immunostaining of CKβBP2/CRIF1 and STAT3 in adjacent
microtome thin sections of a prostate cancer tissue microarray to determine whether the two
proteins are localized in the same cells. Proteins were analyzed by immunostaining 25 cores
each of human BPH, androgen-dependent and castration-recurrent prostate cancer (Fig. 8).
Staining of CKβBP2/CRIF1 in BPH was mainly in stromal cells with weaker staining of
epithelial cells. CKβBP2/CRIF1 staining was strongest in fibromuscular cells of stroma. In
androgen-dependent prostate cancer, CKβBP2/CRIF1 staining remained similar in stroma
but was increased in epithelial cells compared to BPH and was mainly in the cytoplasm of
epithelial cells (Fig. 8). In castration-recurrent prostate cancer, CKβBP2/CRIF1 staining of
epithelium decreased compared to androgen-dependent prostate cancer (Fig. 8). In a subset
of cores (20%) CKβBP2/CRIF1 staining was not detected in epithelial cells of castration-
recurrent prostate cancer. Boundaries between epithelial and stromal cells were often
obscure in castration recurrent prostate cancer.
STAT3 immunostaining was nuclear and cytoplasmic throughout the glandular epithelium
and stroma. STAT3 protein was present wherever CKβBP2/CRIF1 protein was expressed in
BPH and prostate cancer (Fig. 8). STAT3 is activated in prostate cancer (Dhir et al., 2002),
can bind AR (Matsuda et al., 2001) and stimulates the growth of prostate cancer cells (Ni et
al., 2000).
4. Discussion
CKβBP2/CRIF1 functioned as an AR corepressor by binding the AR C-terminal region and
inhibiting the AR N/C interaction, wherein the FXXLF αhelical motif (23FQNLF27) in the
AR N-terminus binds the hydrophobic AF2 region in the C-terminus. CKβBP2/CRIF1
binding to the C-terminal region of AR also competed for binding of the p160 coactivator
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TIF2 to the AR C-terminal region, an interaction involving a TIF2 αhelical LXXLL motif
(He et al., 2001, 2004). CKβBP2/CRIF1 did not bind TIF2, but inhibited TIF2 binding to
AR. However, higher amounts of TIF2 could overcome CKβBP2/CRIF1 inhibition of AR
transcriptional activity in CV1 cells.
Our evidence that CKβBP2/CRIF1 interacts directly with the AR C-terminus differs from
another study (Suh JH et al., 2008) where interaction with the AR N-terminus in a pull-down
assay was stronger than with the AR C-terminus. The difference may be due to the
androgen-dependent nature of CKβBP2/CRIF1 binding to the AR ligand-binding domain.
However, we cannot rule out that the hinge region 33 amino acids 624-656, present in our
construct but not that of Shu J.H. et al. 2008, played a role in the binding difference with
Shu J.H. et al.
We found that CKβBP2/CRIF1 also inhibited the constitutive transcriptional activity of
AR-1–660, an AR N-terminal and DNA binding domain fragment, alone or in the presence
of MAGE-A11. This inhibition of transcriptional activity may reflect an interaction of
CKβBP2/CRIF1 with the AR N-terminal region, although this appeared weaker than the
androgen-dependent binding of CKβBP2/CRIF1 to the AR C-terminal domain in affinity
matrix assays.
MAGE-A11 is an AR coregulator that interacts with the AR N-terminal FXXLF motif
region. Binding of MAGE-A11 to the FXXLF motif can compete with the AR N/C
interaction between the AR FXXLF motif and AF2 in the AR ligand binding domain (Bai et
al., 2005; Bai and Wilson, 2008). MAGE-A11 increases AR transcriptional activity by
binding and promoting AR complexes with TIF2 (Askew et al., 2009) and p300 (Askew et
al., 2010). p160 coactivators such as TIF2 bind the AR N-terminal region (Bevan et al.,
1999). However, an intermediary protein may modulate these p160 interactions with the
unstructured AR N-terminus (Lavery and McEwan, 2008a,b). In prostate cancer cells with
higher MAGE-A11 protein expression, TIF2 may be linked to the AR N-terminus in part
through its binding to MAGE-A11 (Askew et al., 2009). This suggested that CKβBP2/
CRIF1 might also inhibit AR action by interfering with coregulators that bind the AR N-
terminal region.
The AR N/C interaction brings together the unstructured N-terminal region with the highly
structured C-terminal region and has a stabilizing effect on AR by slowing the dissociation
rate of bound DHT (He et al., 2002, 2004, 2006). The AR N/C interaction may influence
coactivator interacting surfaces in AF1 in the N-terminal region (Lavery and McEwan,
2008a,b). Several lines of evidence indicate that the AR N/C interaction has an essential role
in transcriptional activity (Li et al., 2006). AR mutations that interfere with the N/C
interaction or its effects on AR coregulator interactions are associated with partial androgen
insensitivity in humans (Quigley et al., 2004; Lagarde et al., 2012). Moreover, inhibition of
the AR N/C interaction by other AR corepressors (Burd et al., 2006) may reflect the
importance of this domain interaction in AR functional activity.
Other AR corepressors that inhibit the AR N/C interaction are cyclin D1 (Burd et al., 2005,
2006), SMRT (Dotzlaw et al., 2002; Liao et al., 2003) and NCoR (Cheng et al., 2002;
Berrevoets et al., 2004; Wu et al., 2006; Hodgson et al., 2008) that interacts with both N and
C terminal regions of AR. NCoR inhibition of AR resembles that of CKβBP2/CRIF1 in that
its AR inhibitory effect in the presence of R1881 can be reversed by TIF2 (Berrevoets et al.,
2004), suggesting competition between NCoR and TIF2 for binding sites on ligand activated
AR. Binding of NCoR to AR can be increased by antiandrogens (Dotzlaw et al., 2002;
Berrevoets et al., 2004; Wu et al., 2006; Hodgson et al., 2008).
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In the PPC-1 cell line derived from a primary human prostate cancer, the histone deacetylase
inhibitor trichostatin A abolished the repressor activity of CKβBP2/CRIF1 on AR
transcriptional activity and this effect was dependent on histone deacetylase-4 (HDAC-4)
activity (Suh et al., 2008). HDAC-4 was present in nuclei of castration-recurrent prostate
cancer (Halkidou et al., 2004). Class 1 HDACs 1–3 are also expressed in prostate cancers
(Witt et al., 2009). We found a variety of HDAC mRNAs in a small group of prostate
cancers including HDAC-4 (data not shown). A number of AR corepressors recruit HDACs
(Burd et al., 2006; Gross et al., 2004) and may form complexes that control HDAC turnover
(Guo et al., 2012).
The AR inhibitory activity of CKβBP2/CRIF1 in CV1 cells resided mainly in its C-terminal
region. Similarly, C-terminal CKβBP2/CRIF1-99–222 exhibited stronger AR binding than
the N-terminal region in a yeast interaction assay and had stronger AR repressor activity in
HEK-293 cells (Suh et al., 2008). We identified a 49 amino acid CKβBP2/CRIF1-158–206
fragment that retained AR binding activity and strong inhibition of AR transcriptional
activity. This fragment contains a potential coiled-coil region of α-helices and includes an
FXXLL motif similar to the AR N-terminal FXXLF motif, suggesting that like the AR
FXXLF motif, it might confer binding to AR AF2. However, mutation of this motif to
FXXAA in CKβBP2/CRIF1 7-222 did not alter binding to full-length AR and caused only
slight inhibition of AR transcriptional activity compared to the parent fragment containing
FXXLL. In murine C2C12 skeletal muscle cells, C-terminal CKβBP2/CRIF1-99-222 was a
stronger inhibitor of Nurr-77 transactivation than was the N-terminal region of CKβBP2/
CRIF1 (Park et al., 2005).
CKβBP2/CRIF1 was reported to enhance the actions of GADD45 (Chung et al., 2003), a
p53 induced DNA damage and cell stress response protein (Carrier et al., 1999; Liebermann
and Hoffman, 2008). As participants in the cell response to DNA damage, CKβBP2/CRIF1
and other corepressors, forkhead transcription factor FoxO1 (Ma et al., 2009) and
checkpoint protein hRAD9 (Wang et al., 2004), also inhibited the AR N/C interaction.
FoxO1 binding to the AR N-terminal region interfered with the AR N/C interaction, blocked
N-terminal binding of a p160 coactivator and inhibited AR transcriptional activation. AKT
phosphorylation of FoxO1 prevented its AR corepressor activity and PTEN suppressed this
action of AKT. FoxO1 repressor activity was also inhibited by CDK2 activity, and when
CDK2 activity was abolished in response to DNA damage, FoxO1 was activated (Huang
and Tindall, 2007). In this connection, CKβBP2/CRIF1 was also reported to inhibit CDK2
activity (Chung et al., 2003) and thereby may contribute to an increase in FoxO1 corepressor
activity. hRAD9 is a member of the RAD family of checkpoint proteins and a
multifunctional sensor and regulator of the cellular response to DNA damage involved in
DNA repair, checkpoint activation, cell cycle regulation and apoptosis signaling (Ishikawa
et al., 2007). An FXXLF motif in the hRAD9 C-terminal region interacted with the AR C-
terminal region, presumably AF2, inhibited the AR N/C interaction and AR transcriptional
activation (Wang et al., 2004).
Loss of CKβBP2/CRIF1 may have a growth stimulating effect in some cells as a
consequence of removing growth inhibition by CKβBP2/CRIF1 unrelated to AR. For
example, NAC-1, a BTB/POZ protein, repressed transcription of the CKβBP2/CRIF1 gene.
In HeLa cells, the increase in CKβBP2/CRIF1 expression resulting from silencing NAC-1
was associated with growth inhibition in cell culture and xenographs (Nakayama et al.,
2006). Since HeLa cells contain low levels of AR and their growth is not stimulated by
androgen, inhibition of growth associated with an increase in CKβBP2/CRIF1 protein may
have resulted from tumor suppressor effects of CKβBP2/CRIF1 similar to those of
GADD45y Similarly, castration recurrent prostate cancer epithelial cells with a lower
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amount of CKβBP2/CRIF1 protein may have a selective growth advantage due to increased
transcriptional activity of AR.
Recent studies suggest that CRIF1 has a role in oxidative phosphorylation through the
integration of polypeptides into the mitochondrial membrane (Kim et al., 2012l; Shin et al.
2013) and that is part of the mammalian ribosome (Koc et al. 2013). In addition, CRIF1 has
a role in oxidative phosphorylation in mouse adipose tissue (Ryu et al. 2013). Other
evidence supports multiple functions of CKβBP2/CRIF1 in transcription factor regulation.
CKβBP2/CRIF1 is a coactivator of ELF3 (E74-like factor 3) (Kwon et al., 2009) and STAT3
(Kwon et al., 2008). CKβBP2/CRIF1 down-regulates the transcription factor NRF2 by
promoting ubiquitination and degradation (Kang et al., 2010). In our studies, CKβBP2/
CRIF1 was an activator of the cytomegalovirus promoter but not the simian virus 40
promoter (Fig. S5).
Multifunctional effects of CKβBP2/CRIF1 may regulate actions of AR, STAT3 and other
transcription factors in prostate reactive stroma and in epithelium that control
vascularization and growth of prostate cancer (Berry et al., 2008; Yang et al., 2005;
Montecinos et al., 2012).
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• CKβBP2/CRIF1 is a multifunctional corepressor of androgen receptor (AR)
transcriptional activity through inhibition of the AR N/C interaction
CKβBP2/CRIF1 binds STAT3 and STAT3 is expressed with CKβBP2/CRIF1 in
prostate cancer
action of STAT3 on prostate cancer may offset CKβBP2/CRIF1 inhibition of
AR and allow prostate growth
Tan et al. Page 18













Figure 1. CKβBP2/CRIF1 interacts with AR and colocalizes with AR in chromatin
(A) CKβBP2/CRIF1 colocalized with AR in nuclei. pSGFLAG-CKβBP2/CRIF1 and pSG-
AR were cotransfected into COS cells in the absence (top) or presence (bottom) of 10 nM
DHT. Immunofluoresence for AR (green) and CKβBP2/CRIF1 (red) shows CKβBP2/CRIF1
shows typical nuclear and perinuclear localization in the absence of DHT and nuclear in the
presence of DHT while AR is cytoplasmic in the absence of DHT and nuclear in the
presence of DHT. Nuclear colocalization of CKβBP2/CRIF1 and AR in the presence of
DHT is demonstrated by merged images (yellow). (B) FLAG-CKβBP2/CRIF1
coimmunoprecipitated with AR in the presence of DHT. AR was cotransfected in COS cells
with control pSGFLAG (lanes 1, 2), truncated FLAG-CKβBP2/CRIF1 (aa 7–222, lanes 3, 4)
or full-length FLAG-CKβBP2/CRIF1 (aa 1–222, lanes 5, 6) in the absence (-) and presence
(+) of 10 nM DHT. Protein extracts were immunoprecipitated with FLAG monoclonal
antibody affinity resin and AR (indicated by arrow) was visualized by western blotting with
AR specific antibody AR32 (30). CKβBP2/CRIF1 in cell extracts was analyzed by western
blotting using FLAG monoclonal antibody. (C) Chromatin immunoprecipitation was
performed in CWR-R1 cells showing endogenous AR and CKβBP2/CRIF1 localization at
the PSA gene enhancer at 3 and 6 hrs compared to IgG control *p<0.01. (D) DNA binding
was assayed in COS cells as described in Experimental Procedures. In contrast to AR,
CKβBP2/CRIF1 did not bind to PSA enhancer DNA.
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Figure 2. CKβBP2/CRIF1 inhibits AR transcriptional activation of MMTV-Luc in transient
cotransfection assays
CV1 cells in 6 cm dishes were cotransfected with MMTV-Luc (0.5 μg) and pSG-AR (0.1
μg) together with pSG5FLAG control (0.1 and 0.5 μg) or pSGFLAG-CKβBP2/CRIF1-7-222
(0.1 and 0.5 μg). Cells were incubated with and without 0.1 nM DHT and luciferase activity
assayed. Error bars represent ± SEM. CKβBP2/CRIF1 repressed AR transactivation at 0.1
μg *(p<0.001), and 0.5 μg *(p<0.001) compared to pSG5FLAG control 0.01 μg and 0.5 μg
respectively.
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Figure 3. CKβBP2/CRIF1 inhibits AR N-terminal and TIF2 interactions with the AR C-terminal
region
Schematic of mammalian two-hybrid assay is shown at the top. (A) Gal-AR-624–919 (AR
C-terminal region) (50 ng) and 0.1 μg 5XGAL4Luc were cotransfected into HeLa cells with
50 ng VP-AR-1-660 (AR N-terminal region and DNA binding domain) or 50 ng VP-TIF2.1
(TIF2-624-1287) together with pSGFLAG control or pSGFLAG CKβBP2/CRIF1 expression
vectors. Cells were incubated with and without 10 nM DHT and luciferase activity was
measured. CKβBP2/CRIF1 inhibited both AR1-660 and TIF2 interactions with AR 624-919
** (p<0.01) compared to equal amount of pSGFLAG control. (B) CKβBP2/CRIF1
inhibition of AR transcriptional activation rescued by TIF2. CV1 cells in 6 cm dishes were
co-transfected with pSG-AR (0.1 μg) and MMTV-Luc (0.5 μg) together with pSGFLAG-
CKβBP2/CRIF1 (0.5 μg) or pSGFLAG control (0.5 μg), each with pSGFLAG-TIF2
expression vector (0.1 μg or 0.5 μg) or the same amounts of control vector. Cells were
incubated in the absence and presence of 0.1 nM DHT and luciferase activity assayed.
CKβBP2/CRIF1 repressed AR transactivation in the presence of pSGFLAG control and
TIF2 0.1 μg *(p<0.01) but not in the presence of TIF2 0.5 μg (C) Preference for binding of
CKβBP2/CRIF1 to the AR ligand binding domain. Glutathione-Sepharose affinity matrix
assay of [35S]CKβBP2/CRIF1-7-222 binding to GST-glutathione-Sepharose control (C),
GST-AR-1-503 N-terminal domain, GST-AR-544-634 DNA binding domain, GST-
AR-624-919 ligand binding domain. Binding was assayed in the presence of 0.1 nM DHT.
Error bars represent ± SEM.
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Figure 4. Constitutive transcriptional activity of AR-1-660 is inhibited by CKβBP2/CRIF1 in the
absence and presence of MAGE-A11 or MAGE-A11 plus the p160 coactivator, TIF2
(A) CV1 cells in 6 cm dishes were transfected with pCMVAR-1-660 (50 ng) and MMTV-
Luc (5 μg) together with pSG-FLAG-CKβBP2/CRIF1 or pSG-FLAG-vector control (2 μg).
Cells were incubated without DHT and luciferase activity assayed. (B) CV1 cells were
transfected with pCMVAR-1-660 (50 ng) and PSA-Enh-Luc (5 μg) together with pSG-
FLAG-CKβBP2/CRIF1 or pSG-FLAG-vector control (2 μg), each in the presence or
absence of the AR coregulator pSG-MAGE-A11 (2 μg). p5 indicates pCMV control vector
for AR. Cells were incubated in the absence of hormone and luciferase activity assayed.
Error bars represent ± SEM. Results are representative of three experiments, each done in
triplicate.
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Figure 5. Regional sites of CKβBP2/CRIF1 and AR interactions
Schematic of CKβBP2/CRIF1 full-length (amino acid residues 1-222) is shown with
CKβBP2/CRIF1 fragments 7-157, 158-206 and 7-222 containing a mutation of the FXXAA
motif. (A) C-terminal region of CKβBP2/CRIF1-158-206 was sufficient for AR
transcriptional repression. MMTV-Luc (0.5 μg) and pSGFLAG-AR (0.1 μg) were
cotransfected in CV1 cells in 6 cm dishes with and without control vector pSGFLAG (0.5
μg), CKβBP2/CRIF1-7-222, 7-157, 158-206 or 7-222 with FXXLL (175FQELL179) mutated
to FXXAA. Incubations were in the presence or absence of 0.1 nM DHT. Error bars
represent ± SEM. (B) CKβBP2/CRIF1 N-terminal residue 7-157 and C-terminal residue
158-206 fragments interact with full-length AR. AR interaction with FLAG-CKβBP2/CRIF1
amino acid residues 7-222, 7-157 and 158-206 and the pSGFLAG empty vector control was
compared by coimmunoprecipitation assay in lysates of cotransfected COS cells incubated
in the presence and absence of 10 nM DHT. Immunoprecipitation was preformed using
FLAG affinity resin antibody and AR was visualized by western blotting using AR 32
antibody. Expression levels of AR and CKβBP2/CRIF1 were assayed by western blotting
transfected COS cell protein extracts. FLAG-CKβBP2/CRIF1 158-206 was too small to
identify on this gel. Its expression is shown on a 4-20% gradient gel (Fig. S4) (C) The
FXXLL motif of CKβBP2/CRIF1 is not required for AR binding. FLAG-CKβBP2/
CRIF1-7-222 wild-type or with 175FQEAA179 FXXAA mutation and control pSGFLAG
empty vector were cotransfected individually with AR into COS cells and incubated in the
presence and absence of 10 nM DHT. Immunoprecipitation was performed using FLAG
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antibody affinity resin and AR was visualized by western blotting with AR 32 antibody.
Expression levels of CKβBP2/CRIF1 and AR in COS cell protein extracts were assayed by
western blotting. Error bars represent ± SEM. Results are representative of three
experiments.
Tan et al. Page 24













Figure 6. CKβBP2/CRIF1 inhibits endogenous AR transcriptional activation in CWR-R1 human
prostate cancer cells
(A) CWR-R1 cells in 6 well plates were transfected with MMTV-Luc (0.1 μg) and 0.25 μg
pSG5FLAG-control vector, pSGFLAG-CKβBP2/CRIF1-1-222 or pSGFLAG-CKβBP2/
CRIF1-7-222. Cells were incubated with and without 0.1 nM DHT and luciferase activity
measured. Error barsrepresent ± SEM. (B) Inhibition of recombinant CKβBP2/CRIF1
protein expression by CKβBP2/CRIF1 siRNA 1. COS cells in 6 cm dishes were transfected
with pSGFLAG-CKβBP2/CRIF1 (lane 1), pSGFLAG-CKβBP2/CRIF1 with the addition of
20 nM CKβBP2/CRIF1 siRNA 1 (lane 2) or siRNA 2 (lane 3). Cells were incubated for 48 h
and protein levels in cell lysates assayed by western blotting using FLAG monoclonal
antibody. (C) CKβBP2/CRIF1 siRNA-1 prevented recombinant CKβBP2/CRIF1 inhibition
of AR transcriptional activation. CV1 cells in 6 cm dishes were transfected with 0.5 μg
MMTV-Luc, 0.1 μg pSG-AR and 0.5 μg pSGFLAG-CKβBP2/CRIF1 or control vectors,
with addition of 10 nM CKβBP2/CRIF1 siRNA-1 or siRNA-2. Cells were incubated with
0.01 nM DHT and luciferase activity assayed. Error bars represent ± SEM. (D) Endogenous
AR transcriptional activation in CWR-R1 cells was increased by inhibition of CKβBP2/
CRIF1 expression. CWR-R1 cells in 6 well plates were transfected with MMTV-Luc (0.1
μg) using Effectene and increasing amounts (5-20 nM) CKβBP2/CRIF1 siRNA-1 or
siRNA-2. Cells were incubated in the presence and absence of DHT and luciferase activity
assayed. Fold inductions indicated by the number above the bar represent luciferase activity
in the presence of DHT divided by activity in the absence of DHT. Error bars represent ±
SEM. Results are representative of two experiments, each performed in triplicate.
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Fig. 7. CKβBP2/CRIF1 mRNA in benign prostatic hyperplasia (BPH), androgen-dependent
prostate cancer (AD-CaP) and castration-recurrent prostate cancer (CR-CaP)
RNA was extracted using Trizol (Qiagen) from 4 or 5 different specimens of BPH, AD-CaP
and CR-CaP and reverse transcribed using Super Script II Reverse Transcriptase
(Invitrogen). RT-PCR using 100 ng cDNA was performed in a Roche Light Cycler with
Quanti Tech SYBR Green (Qiagen). Gene expression was calculated using a standard curve.
Relative expression was defined as sample gene expression divided by internal control gene
expression as described in Methods. Error bars represent ± SEM. Results are representative
of two experiments, each performed in triplicate.
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Figure 8. CKβBP2/CRIF1 and STAT3 expression in adjacent sections of tissue microarrays of
human benign prostatic hyperplasia, androgen-dependent and castration-recurrent prostate
cancer
Representative pictures show human benign prostatic hyperplasia (BPH, top), androgen-
dependent (AD-CaP, middle) and castration-recurrent prostate cancer (CR-CaP, bottom).
Tissue microarray adjacent thin sections were prepared and immunostained as described in
Methods. CKβBP2/CRIF1 (CKβBP2, left) and STAT3 (right). CKβBP2/CRIF1 protein in
epithelial cells: AD-CaP > BPH (p<0.001), CR-CaP < AD-CaP (p<0.014); CKβBP2/CRIF1
protein in stromal cells: staining is mainly in myofibroblasts. No difference overall between
staining of stroma in BPH, AD-CaP and CR-CaP. STAT3 protein was present where
CKβBP2/CRIF1 protein was expressed in BPH and prostate cancer.
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